AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3730264 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 0
Study 3730264 — intervention group
Group type: COMPARATOR
Intervention: Low dose salbutamol treatment
Number of subjects: 0
Study 29357943 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized feedback letters based on accelerometer data
Number of subjects: 100
Study 29357943 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 100
Study 26951845 — intervention group
Group type: EXPERIMENTAL
Intervention: PEITC (10 mg in 1 mL of olive oil, 4 times per day)
Number of subjects: 82
Study 26951845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 23532433 — intervention group
Group type: EXPERIMENTAL
Intervention: FemoSeal® VCD
Number of subjects: 1001
Study 23532433 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 1001
Study 23575741 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram (ESC) 10-20 mg/day
Number of subjects: 20
Study 23575741 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 20205227 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate (CHO) treatment
Number of subjects: 142
Study 20205227 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 142
Study 20205227 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate (CHO) treatment (in subgroup without epidural blockade or laparoscopic surgery)
Number of subjects: 142
Study 20205227 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (in subgroup without epidural blockade or laparoscopic surgery)
Number of subjects: 142
Study 18769684 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg position at 30 degrees plus 5 manual inflations of the lungs
Number of subjects: 116
Study 18769684 — intervention group
Group type: COMPARATOR
Intervention: Standard passive deflation of residual abdominal carbon dioxide through the cannula
Number of subjects: 116
Study 16889546 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV‐IVIG
Number of subjects: 82
Study 16889546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 12912805 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysmal wall from patients with cerebral aneurysms
Number of subjects: 0
Study 12912805 — intervention group
Group type: COMPARATOR
Intervention: Control cortical arterial wall
Number of subjects: 0
Study 10731405 — intervention group
Group type: EXPERIMENTAL
Intervention: Original images
Number of subjects: 71
Study 10731405 — intervention group
Group type: COMPARATOR
Intervention: Compression ratio 6:1
Number of subjects: 71
Study 10731405 — intervention group
Group type: COMPARATOR
Intervention: Compression ratio 10:1
Number of subjects: 71
Study 10731405 — intervention group
Group type: COMPARATOR
Intervention: Compression ratio 16:1
Number of subjects: 71
Study 8800106 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy for acute myocardial infarction
Number of subjects: 481
Study 1503488 — intervention group
Group type: EXPERIMENTAL
Intervention: 254-S (80 to 100 mg/m2, administered at least 2 times at 4-week intervals)
Number of subjects: 62
Study 1503488 — intervention group
Group type: EXPERIMENTAL
Intervention: 254-S plus vindesine
Number of subjects: 62
Study 1503488 — intervention group
Group type: COMPARATOR
Intervention: cisplatin plus vindesine
Number of subjects: 62
Study 6394228 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor XIII concentrate (750 IU for 3 days)
Number of subjects: 61
Study 6394228 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor XIII concentrate (1500 IU for 3 days)
Number of subjects: 61
Study 6394228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no factor XIII substitution)
Number of subjects: 61
Study 31872905 — intervention group
Group type: EXPERIMENTAL
Intervention: Fantastical television content
Number of subjects: 80
Study 31872905 — intervention group
Group type: COMPARATOR
Intervention: Non-fantastical television content
Number of subjects: 80
Study 31867651 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate nicotine reduction to 0.04 mg nicotine/g of tobacco
Number of subjects: 1250
Study 31867651 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual nicotine reduction to 0.04 mg nicotine/g of tobacco
Number of subjects: 1250
Study 31867651 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate nicotine reduction
Number of subjects: 1250
Study 31867651 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual nicotine reduction
Number of subjects: 1250
Study 31867651 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 1250
Study 28330941 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-driven clinical pathway (weaning salbutamol frequency using an asthma scoring tool)
Number of subjects: 113
Study 28330941 — intervention group
Group type: COMPARATOR
Intervention: Standard care (physicians weaning salbutamol frequency)
Number of subjects: 113
Study 25864950 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous D₂ blockade (estimated trough D2 blockade of >65%)
Number of subjects: 68
Study 25864950 — intervention group
Group type: COMPARATOR
Intervention: Non-continuous blockade (estimated peak level of >65% with an estimated trough level of <65%)
Number of subjects: 68
Study 23805925 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week gentle yoga intervention
Number of subjects: 12
Study 21665108 — intervention group
Group type: EXPERIMENTAL
Intervention: Backnobber II device
Number of subjects: 28
Study 21665108 — intervention group
Group type: COMPARATOR
Intervention: Control (non-treated MTrP)
Number of subjects: 28
Study 19845495 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 1354
Study 19845495 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 1354
Study 19845495 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (in patients aged >65 years)
Number of subjects: 1354
Study 19845495 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (in patients aged >65 years)
Number of subjects: 1354
Study 16475483 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative EEG assessment post-liver transplantation
Number of subjects: 14
Study 16475483 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative EEG assessment post-liver transplantation (without complications)
Number of subjects: 14
Study 14766715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 5 g ml(‐1)
Number of subjects: 1250
Study 14766715 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 5 g ml(‐1)
Number of subjects: 1250
Study 14766715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 g ml(‐1)
Number of subjects: 1250
Study 14766715 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 7.5 g ml(‐1)
Number of subjects: 1250
Study 14766715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose concentrations (10, 20, 30, 50, and 80 g ml(‐1)) added to 5 g ml(‐1) solutions
Number of subjects: 1250
Study 11176015 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg valsartan
Number of subjects: 250
Study 11176015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 9290986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate administration
Number of subjects: 20
Study 8318480 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketanserin 0.5%
Number of subjects: 20
Study 8318480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3013495 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (2 g/day for 10 days)
Number of subjects: 0
Study 3013495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30988478 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing intervention that highlights incompatibility of food marketing with adolescent values
Number of subjects: 0
Study 28506314 — intervention group
Group type: EXPERIMENTAL
Intervention: ILMOD group
Number of subjects: 31
Study 28506314 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 25226048 — intervention group
Group type: COMPARATOR
Intervention: SnF2 gel 2500 ppm F (5 min) every third day
Number of subjects: 8
Study 25226048 — intervention group
Group type: COMPARATOR
Intervention: NaF toothpaste 5000 ppm F (5 min every third day and 2 min other days)
Number of subjects: 8
Study 25226048 — intervention group
Group type: COMPARATOR
Intervention: NaF toothpaste 1450 ppm F (2 min every day)
Number of subjects: 8
Study 25226048 — intervention group
Group type: COMPARATOR
Intervention: Control (no fluoride treatment)
Number of subjects: 8
Study 22860989 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichen sclerosus group (n=48)
Number of subjects: 92
Study 22860989 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=44)
Number of subjects: 92
Study 21420555 — intervention group
Group type: EXPERIMENTAL
Intervention: NASHA Dx (transanal submucosal injections)
Number of subjects: 206
Study 21420555 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 206
Study 19797376 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 325
Study 19797376 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 325
Study 17022207 — intervention group
Group type: EXPERIMENTAL
Intervention: Monte Carlo dose engine (MCDE)
Number of subjects: 10
Study 17022207 — intervention group
Group type: COMPARATOR
Intervention: Pinnacle‐CS
Number of subjects: 10
Study 17022207 — intervention group
Group type: COMPARATOR
Intervention: Helax‐CC
Number of subjects: 10
Study 17022207 — intervention group
Group type: COMPARATOR
Intervention: Helax‐PB
Number of subjects: 10
Study 17022207 — intervention group
Group type: EXPERIMENTAL
Intervention: All algorithms (MCDE, Pinnacle‐CS, Helax‐CC, Helax‐PB)
Number of subjects: 10
Study 15386949 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute dipterex poisoning (ADP) patients
Number of subjects: 50
Study 15386949 — intervention group
Group type: COMPARATOR
Intervention: Healthy adult volunteers (HAVs)
Number of subjects: 50
Study 12616820 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy performed in 43 clinics and departments
Number of subjects: 47
Study 12616820 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy performed in case of cardiac or upper third tumors
Number of subjects: 47
Study 12616820 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy performed in case of suspicious hilar lymph nodes
Number of subjects: 47
Study 12616820 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined, extended operation performed if tumorous infiltrates surrounding organs
Number of subjects: 47
Study 12616820 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined, extended operation performed as palliation
Number of subjects: 47
Study 9834040 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (25 mg) as a CYP1A2 inhibitor
Number of subjects: 12
Study 9834040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (100 mg) as a CYP3A4 inhibitor
Number of subjects: 12
Study 9834040 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone (40 mg)
Number of subjects: 12
Study 8590556 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 20
Study 8590556 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 20
Study 8590556 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 20
Study 8590556 — intervention group
Group type: COMPARATOR
Intervention: Control situation (no treatment)
Number of subjects: 20
Study 2636699 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin nasal spray
Number of subjects: 10
Study 2636699 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin tablets
Number of subjects: 10
Study 1098705 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic anticholinergic drug (SCH 10000)
Number of subjects: 10
Study 1098705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31742366 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity laser therapy (HILT) with a power of 1.6 W and low fluence of 8 J/cm2
Number of subjects: 98
Study 31742366 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 98
Study 31742366 — intervention group
Group type: COMPARATOR
Intervention: Exercise-only control group
Number of subjects: 98
Study 31282081 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day therapy with levofloxacin (750 mg), clarithromycin-MR (1 g), rabeprazole (60 mg), and bismuth subsalicylate (1,048 mg)
Number of subjects: 100
Study 31282081 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day therapy with levofloxacin (750 mg), clarithromycin-MR (1 g), rabeprazole (60 mg), and bismuth subsalicylate (1,048 mg)
Number of subjects: 100
Study 28360432 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 min per week of aerobic exercise (ALPHA trial)
Number of subjects: 360
Study 28360432 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min per week of aerobic exercise (BETA trial)
Number of subjects: 360
Study 28360432 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 min per week of aerobic exercise (BETA trial)
Number of subjects: 360
Study 28360432 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in VO2peak
Number of subjects: 360
Study 25633037 — intervention group
Group type: EXPERIMENTAL
Intervention: Home mailing of self-sampler
Number of subjects: 14041
Study 25633037 — intervention group
Group type: EXPERIMENTAL
Intervention: Picking up self-sampler at pharmacy
Number of subjects: 14041
Study 25633037 — intervention group
Group type: COMPARATOR
Intervention: Standard reminder letter (control)
Number of subjects: 14041
Study 24283282 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,426 ppm fluoride toothpaste
Number of subjects: 0
Study 24283282 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 ppm fluoride toothpaste
Number of subjects: 0
Study 24283282 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm fluoride toothpaste
Number of subjects: 0
Study 24283282 — intervention group
Group type: COMPARATOR
Intervention: 0 ppm fluoride toothpaste (placebo)
Number of subjects: 0
Study 20614474 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate 1200 mg daily
Number of subjects: 1460
Study 20614474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1460
Study 19841844 — intervention group
Group type: EXPERIMENTAL
Intervention: Function-centred inpatient treatment
Number of subjects: 174
Study 19841844 — intervention group
Group type: COMPARATOR
Intervention: Pain-centred inpatient treatment
Number of subjects: 174
Study 18163016 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 206
Study 18163016 — intervention group
Group type: COMPARATOR
Intervention: Heparin and at least 4 weeks of oral anticoagulation therapy (OAT)
Number of subjects: 206
Study 14979817 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative comprehension with varying temporal distances between events
Number of subjects: 0
Study 14979817 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal distance varied in terms of the duration of an intervening event
Number of subjects: 0
Study 14979817 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal distance varied in terms of a temporal shift
Number of subjects: 0
Study 11820234 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual art dialogues
Number of subjects: 267
Study 11820234 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visual art dialogues)
Number of subjects: 267
Study 9516063 — intervention group
Group type: COMPARATOR
Intervention: Galanin infusion (8 microg/Kg/h) in healthy volunteers (group I)
Number of subjects: 19
Study 9516063 — intervention group
Group type: COMPARATOR
Intervention: Galanin infusion (8 microg/Kg/h) in cured acromegaly patients (group III)
Number of subjects: 19
Study 9516063 — intervention group
Group type: EXPERIMENTAL
Intervention: Galanin infusion (8 microg/Kg/h) in patients with active acromegaly (group II)
Number of subjects: 19
Study 9516063 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AUC in groups I and III vs group II
Number of subjects: 19
Study 8034992 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin, 500 mg once daily
Number of subjects: 591
Study 8034992 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin, 250 mg four times daily
Number of subjects: 591
Study 29522927 — intervention group
Group type: EXPERIMENTAL
Intervention: Expand Your Horizon (three online body functionality writing exercises)
Number of subjects: 261
Study 29522927 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 261
Study 29901376 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughing training program for 3 days a week, 1 hour a day for 8 consecutive weeks
Number of subjects: 38
Study 29901376 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughing training program
Number of subjects: 38
Study 29901376 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting in the same room)
Number of subjects: 38
Study 23947316 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention delivering self-management training through 36 home visits over 2 years
Number of subjects: 144
Study 23947316 — intervention group
Group type: COMPARATOR
Intervention: Bilingual control newsletter delivering the same information on the same schedule
Number of subjects: 144
Study 21743037 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductive reasoning training intervention
Number of subjects: 0
Study 21743037 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 20019638 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (n = 65), 8 core exercises, 2 sets of 8 repetitions at 70%-80% of one-repetition maximum, 3 times weekly
Number of subjects: 122
Study 20019638 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (n = 65)
Number of subjects: 122
Study 20019638 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tertile of SQ (2.5% attendance)
Number of subjects: 122
Study 20019638 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of SQ (64% attendance)
Number of subjects: 122
Study 20019638 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 true controls)
Number of subjects: 122
Study 18978250 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (five sessions of individual and family counseling within 3 months of enrollment and continuous availability of ad hoc telephone counseling)
Number of subjects: 158
Study 18978250 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment alone (donepezil prescribed for all patients)
Number of subjects: 158
Study 16413875 — intervention group
Group type: EXPERIMENTAL
Intervention: BMSC transfer
Number of subjects: 67
Study 16413875 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 67
Study 12759327 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite primary outcome measures
Number of subjects: 300276
Study 11272956 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic checklist
Number of subjects: 0
Study 11272956 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 0
Study 8871425 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress inoculation training (SIT) and physical therapy
Number of subjects: 60
Study 8871425 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy only
Number of subjects: 60
Study 1516292 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (mean 27% of energy as protein)
Number of subjects: 5
Study 6419263 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma haloperidol levels (4.2‐11.0 ng/ml) during the first 14 days of treatment
Number of subjects: 14
Study 29727758 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate practice (n=10)
Number of subjects: 18
Study 29727758 — intervention group
Group type: COMPARATOR
Intervention: Self-guided practice (n=8)
Number of subjects: 18
Study 27036077 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous access
Number of subjects: 1416
Study 27036077 — intervention group
Group type: COMPARATOR
Intervention: Surgical access
Number of subjects: 1416
Study 27036077 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1416
Study 24118113 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily biphasic insulin analogue (biphasic insulin aspart 70/30, biphasic insulin aspart 30)
Number of subjects: 100
Study 23176984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 4 mg bupivacaine 0.5% + 25 μg fentanyl
Number of subjects: 60
Study 23176984 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal 50 mg prilocaine 2% + 25 μg fentanyl
Number of subjects: 60
Study 21214129 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%-benzoyl peroxide 2.5% gel
Number of subjects: 2813
Study 21214129 — intervention group
Group type: COMPARATOR
Intervention: Individual active ingredients and vehicle
Number of subjects: 2813
Study 19189678 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick smear layer with different dentin conditioners
Number of subjects: 50
Study 19189678 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin smear layer with different dentin conditioners
Number of subjects: 50
Study 19189678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin conditioners used prior to glass-ionomer adhesive application
Number of subjects: 50
Study 16351670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (1 mg)
Number of subjects: 82
Study 16351670 — intervention group
Group type: COMPARATOR
Intervention: Propafenone (70 mg)
Number of subjects: 82
Study 16351670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 82
Study 16351670 — intervention group
Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 82
Study 12361104 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL ipecac syrup
Number of subjects: 12
Study 12361104 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL ipecac syrup
Number of subjects: 12